BeyondSpring Inc. Reports Q3 2025 Earnings and Strategic Shift

BeyondSpring Inc. reported a Q3 2025 net loss of $4.944 million, an improvement from last year's $4.573 million loss. The company increased its cash position to $12.483 million. A strategic shift involved divesting interests in SEED Therapeutics Inc., reducing ownership to 40.12%, to focus on promising pipelines like Plinabulin. This move aims to optimize resources for cancer therapy development. BeyondSpring remains committed to advancing its clinical-stage products, particularly for chemotherapy-induced neutropenia and non-small cell lung cancer.

BeyondSpring (NASDAQ:BYSI) Issues Quarterly Earnings Results

BeyondSpring (NASDAQ:BYSI) reported a quarterly loss of $0.05 per share. The stock fell 2.5% to $2.15, with a trading volume of 18,532 shares. Geode Capital Management increased its stake in the company by 951.4% in Q2. Weiss Ratings reiterated a 'sell' rating for BeyondSpring. The company focuses on cancer therapies, with its lead asset Plinabulin in Phase III trials for non-small cell lung cancer. Analysts suggest other stocks as better investments.

Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln

BeyondSpring reported a narrowed Q3 net loss of $1.7 million, down from $2.2 million last year. The company highlighted promising results for Plinabulin in NSCLC patients and secured $30 million in financing, achieving IND clearance for the RBM39 program. R&D expenses increased to $1.0 million for the quarter. BeyondSpring aims to advance Plinabulin’s clinical development for improved survival benefits.

BeyondSpring | 8-K: FY2025 Q3 Revenue: USD 0

BeyondSpring Inc. reports reduced net loss from discontinued operations for nine months ended September 2025

BeyondSpring Inc. reported a reduced net loss from discontinued operations of $2.2 million for the nine months ended September 2025, down from $5.0 million in 2024. The company reclassified SEED Therapeutics’ results as discontinued after agreeing to sell most of its Series A-1 Preferred Shares. BeyondSpring's ownership in SEED is expected to drop from 38% to about 14%. Key developments include SEED's $30 million financing and FDA clearance for its IND application. BeyondSpring also reported an 85% disease control rate for its Plinabulin treatment in metastatic NSCLC patients.